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Yeast species such as Saccharomyces cerevisiae are known to be potent activators of the immune sys-
tem. S. cerevisiae activates the innate immune system by engaging pattern recognition receptors such
as toll like receptor 2 (TLR2) and dectin-1. In the current project, we express the immunogenic enve-
lope protein E2 of bovine viral diarrhoea virus (BVDV) on the surface of S. cerevisiae. After successful
expression, components of the innate and adaptive immune response induced by the recombinant S.
cerevisiae in vitro were analysed to determine if expression in yeast enhances the immunogenicity of
the viral protein. Recombinant S. cerevisiae stimulated production of the chemokine CXCL-8 in primary
bovine macrophages, but did no stimulate production of reactive oxygen species (ROS) in the same
cells. Additionally, bovine macrophages primed with S. cerevisiae expressing viral envelope proteins
had a greater capacity for stimulating proliferation of CD4+ T-cells from BVDV-free animals compared
to macrophages primed with envelope protein alone or S. cerevisiae without envelope protein expres-
sion. Heat inactivation of recombinant S. cerevisiae increased ROS production and capacity to stimulate
CD4+ T-cells in macrophages but did not alter CXCL-8 release compared to the live counter-part.
Additionally, heat-inactivation of recombinant S. cerevisiae induced less INFc and IL-4 but equal
amounts of IL-10 compared to live yeast T-cell cultures. Our studies demonstrate a use for S. cerevisiae
as a vehicle for transporting BVDV vaccine antigen to antigen-presenting cell in order to elicit cell-
mediated immunity even in naïve animals.
 2011 Elsevier Ltd. Open access under CC BY license.1. Introduction
Recognition of invading antigen by the immune system is key
for tailoring an appropriate immune response in order to quell
infection. This recognition is facilitated through pattern recogni-
tion receptors (PRRs), which recognise conserved structures on
invading microbes termed pathogen associated molecular patterns
(PAMPs). Ligation of these PAMPs to their corresponding PRRs in-
duces a very specific immune response. Of the many PRRs now
known, the toll like receptors (TLRs) are the best characterised
and most extensively studied.
TLRs 1–10 have been identified in humans and in cattle, and
bovine TLRs have been shown to share high sequence homology
with human TLRs (ranging between 77% and 86% sequencex: +44 1707 652 090.
Clinical Sciences, College of
ation, TX 77843, USA.
 license.similarity at the nucleotide level) (Werling et al., 2006). Of these
TLRs, TLR2 seems to be the one involved in the recognising
antigens from Gram-positive bacteria and fungi, and ligation of
TLR2 induces cellular signalling via NF-kB.
Another group of PRRs are the c-type lectin receptors (CTLRs), of
which dectin-1 is the best characterised. This receptor has been
shown to bind to b-glucan, a component of yeast cell wall. Engage-
ment of dectin-1 facilitates internalisation of yeast particles by
phagocytosis (Dennehy and Brown, 2007; Herre et al., 2004).
Dectin-1 and TLR2 have previously been shown to co-operate in
mounting an immune response to yeast antigen. Receptors co-
localise on the surface of RAW-D1 macrophages (MØ) at the point
of zymosan contact, and also in nascent zymosan-induced phago-
somes (Brown et al., 2003). In addition to these observations, pre-
vious work in our lab has demonstrated that stimulating HEK293
cells transfected with bovine dectin-1 and TLR2 receptors with
zymosan induces co-localisation of receptors at points of zymosan
contact (Willcocks and Werling, unpublished results).
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antigen and co-operate in initiating the ensuing immune re-
sponse, they appear to play very different roles. Experiments by
others also suggest that TLR2 is mainly responsible for the inflam-
matory response to yeast antigen (Gantner et al., 2003; Gersuk
et al., 2006; Underhill, 2007). Cells expressing a mutated murine
TLR2 receptor fail to show NF-kB activity or produce TNF-a in re-
sponse to zymosan compared to cells expressing the wild-type
receptor. However, cells expressing the mutated receptor still en-
gulfed zymosan particles and produced reactive oxygen species
(ROS) with equal efficiency to those expressing the wildtype
receptor indicating that TLR2 is not obligatory for phagocytosis
or production of ROS (Gantner et al., 2003; Underhill et al.,
1999a,b).
Bovine viral diarrhoea virus (BVDV) is a single stranded positive
RNA pestivirus from the family Flaviviridae (Schweizer et al.,
2006). Infection of cattle with BVDV presents a wide spectrum of
disease, ranging from mild acute infection to fatal mucosal disease,
and causes significant loss to the live-stock industry. The USDA li-
cence over 180 commercially available vaccines for BVDV with
varying levels of success and duration of protection (Kelling,
2004). In general, the use of modified live vaccine induces high ti-
tres of virus neutralising antibodies and gives the animal longer
protection from clinical disease than inactivated vaccines. How-
ever, there is a risk that modified-live vaccines can revert to a vir-
ulent form and cause disease and indeed calves vaccinated with
modified live vaccines often develop transient viraemia and shed
vaccine virus (Fulton et al., 2003; Kelling, 2004). Neither modi-
fied-live nor inactivated vaccines allow for discrimination by clin-
ical test as to which animals have been vaccinated and which
animals have contracted BVDV by natural infection. This failure
to discriminate could be rectified by development of an effective
subunit vaccine for BVDV and the bovine immune response to indi-
vidual BVDV antigens has been the subject of much research re-
cently (Thomas et al., 2009). The 53 kDa E2 protein of BVDV is
part of the viral envelope and is widely accepted as being the most
immunogenic protein of this virus with high titres of neutralising
antibodies against E2 being found in the host after infection (Baxi
et al., 2000; Pande et al., 2005; Thomas et al., 2009). For any vac-
cine to be successful, the host immune system must recognise it
as antigenic.
In the current study we chose to assess the value of using re-
combinant Saccharomyces (S.) cerevisiae yeast expressing the BVDV
envelope protein 2 (E2) on its surface as a vaccine candidate for
BVDV, by targeting dectin-1/TLR2 expressed on the surface of bo-
vine macrophages. Due to the immunogenicity of the E2 protein
and ability of yeast species to activate both inflammatory and
phagocytic receptors on antigen presenting cells (APCs) our recom-
binant yeast represents an ideal expression system to determine if
the efficiency of protein sub-unit vaccine may be improved by
expression in yeast, and prevents the negative effects seen when
expressed in baculovirus (Pande et al., 2005).2. Methods and materials
2.1. Animals
Whole blood was collected from healthy Friesian–Holstein bull-
ocks into 10% acid citrate dextrose buffer as anti-coagulant in
accordance with Home Office regulations. All animals were tested
for the absence of BVDV antibodies and viral RNA by the Veterinary
Laboratories Agency (Weybridge, UK) and tested negative for both.
Thus, these animals were naïve with regards to recognising BVDV
derived peptides.2.2. Cloning of BVDV E2 sequence
The partial coding sequence of the BVDV Ky1203ncp E2 gene in
pSecTag (Invitrogen) was kindly provided by Dr. C. Thomas (Royal
Veterinary College) already. To obtain the full coding sequence, this
sequence was amplified by PCR adding start and stop codon on the
50 and 30 end respectively using PCR and forward (50-ATGCAC-
GACTGCAAACC-30) and reverse (50-TGGCCCTAATGAAGCGGTCA-30)
primers. The following PCR conditions were used: 95 C for 2 min
followed by 35 cycles of 95 C for 1 min, 59 C for 1 min, 72 C
for 2 min. After successful cloning of the full E2 sequence was con-
firmed by sequencing, the pYD1 vector was linearised by a double
restriction digest using BamHI and NotI (New England Bio-labs)
and the E2 gene was ligated into the linearised pYD1 vector using
T4 DNA ligase (Promega). Presence of the E2 insert in the correct
orientation and in frame with the pYD1 vector was confirmed by
PCR and sequencing (Gene service, Cambridge, UK).
2.3. Transformation of competent EBY100 S. cerevisiae with pYD1-E2
Competent EBY100 cells pre-prepared using the S. cerevisiae
EasyComp kit (Invitrogen) according to the manufacturer’s instruc-
tions. Stored competent cells were thawed and 50 ll was pipetted
into a sterile Eppendorf tube for each transformation reaction. 1 lg
of pYD1 or pYD1-E2 was added to the cells. An Eppendorf tube con-
taining competent cells but no plasmid DNA was set up as a nega-
tive control. 500 ll of solution 3 of the S. cerevisiae EasyComp kit
(Invitrogen) was added to each transformation tube and tubes
were vortexed for 5 s each. Tubes were incubated at 30 C for
60 min and during this incubation were vortexed every 15 min
for 5 s per tube. After incubation, 100 ll of transformation reaction
from each tube was spread on a separate minimal dextrose plates
pre-spread with 100 ll of 10 mg ml1 L-leucine (Sigma–Aldrich).
Plates were incubated at 30 C for 2–4 days and checked for growth
of transformed colonies.
2.4. Surface protein induction and staining in EBY100 S. cerevisiae
Wild-type EBY100 and EBY100 transformed with the pYD1
plasmid (Invitrogen) containing the E2 gene insert of BVDV or
the empty pYD1 plasmid were grown overnight in 10 ml of YNB-
CAA media containing 2% glucose at 30 C and 250 rpm. The absor-
bance of the overnight cultures was read at OD600 and the cells
were pelleted by centrifugation at 4000g for 10 min at room tem-
perature. The cell pellet was re-suspended to an OD600 of 0.5 in
YNB-CAA medium containing 2% galactose and a volume of cells
equivalent to 2 U OD600 was removed and stored on ice as a zero
time point. Cell cultures were incubated for 48 h at 20 C and
250 rpm with a volume of cells equivalent to 2 U OD600 being re-
moved every 12 h and stored on ice until all time-points were col-
lected. Samples were pelleted and washed with PBS (Sigma) at
4000g at 4 C for 10 min. Cells were suspended in 250 ll of PBS
with 1 mg ml1 BSA (PAA) and 1 lg of X-press antibody (Invitro-
gen) or WB162 antibody (provided by VLA, Weybridge) against
the BVDV E2 protein. Cells were incubated on ice for 30 min with
occasional mixing. Antibody was removed with a centrifugation
step and cells were again washed in PBS. After washing, cell pellet
was re-suspended in 250 ll PBS with 1 mg ml1 BSA and 1 lg don-
key anti-mouse-Alexafluor 488 antibody (Invitrogen). Samples
were incubated on ice and away from light for 30 min with occa-
sional mixing. Antibody was removed with a centrifugation step
and cells were washed twice in PBS. After washing, cells were re-
suspended in 100 ll of PBS and 10 ll of this was spotted on a
microscope slide. A cover slip was applied and cells were viewed
by fluorescent microscopy using 530 nm band-pass filter and
20 magnification lens.
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EBY100-pYD1 or EBY100-pYD1-E2 cells were suspended in
500 ll sterile PBS (Sigma) and incubated at 56 C for 60 min.
Heat-killed yeast was termed DEBY100-pYD1 and DEBY100-
pYD1-E2. The viability of heat-killed cells was determined by plat-
ing on YPD plates.
2.6. Culture of bovine macrophages (MØ)
MØ were prepared as described (Werling et al., 2004). Briefly,
blood was collected from animal in a vacuum bottle containing
10% final volume of ACD anticoagulant buffer, the buffy coat har-
vested, cells washed with citrate-buffer, and red blood cells lysed.
Subsequently, PBMC were generated by density-gradient centrifu-
gation over Histopaque (d = 1.083 g dl1; Sigma) for 45 min, 1200g
at room temperature. The interphase was carefully removed,
washed, cells counted in trypan blue and adjusted to a concentra-
tion of 5  106 cells per ml, placed into Teflon bags and incubated
at 37 C and 5% CO2 for 7 days.
2.7. ELISA for CXCL8
ELISA for CXCL-8 was performed according manufacturer’s rec-
ommendation (R&D Systems). Optical density of each well was
determined using a Spectra Max M2 plate reader (Molecular De-
vices) set to 450 nmwith wavelength correction of 540 nm. Results
were analysed in Excel (Microsoft).
2.8. Measurement of ROS production
1  107 MØ in a volume of 1 ml of HBSS (Gibco) were placed in
sterile 1.5 ml Eppendorf tubes. Cells were stimulated with
1 mg ml1 zymosan, 390 lg ml1 isolated E2 protein, or the equiv-
alent amount of E2 expressed by yeast, resulting in 5ppc EBY100-
pYD1, 5ppc EBY100-pYD1-E2, 5ppc DEBY100-pYD1, 5ppc
DEBY100-pYD1-E2, or HBSS as a negative control. ROS production
was analysed as recently described (Conejeros et al., 2011), and
plates were read at 485 nm excitation and 530 nm emission in a
Spectra Max M2 plate reader (Molecular Devices) and results re-
corded over a 135 min period with readings being taken every
15 min. Results were analysed in Excel (Microsoft).
2.9. T-cell presentation assay
Bovine MØ were seeded at a density of 1  104 per well in
200 ll RPMI (Gibco) supplemented with 10% FCS and 200 Uml1
penicillin and streptomycin in 96-well round bottom plates (Cell-
star). Plates were incubated at 37 C and 5% CO2 for 2 h after which
100 ll of media was removed from each well. Cells were primed
with either 5ppc EBY100-pYD1, 5ppc DEBY100-pYD1, 5ppc
EBY100-pYD1-E2, 5ppc DEBY100-pYD1-E2 or 390 lg ml1 E2 in a
volume of 100 ll media per well. Plates were incubated at 37 C
and 5% CO2 for 2 h after which 100 ll was removed from each well.
CD4+ autologues T cells were prepared by MidiMacs separation
using mAb specific for bovine CD4 (CC8), as described (Werling
et al., 2002). The purity of the cells was evaluated by flow cytom-
etry and shown to be >98%. Subsequently, 1  105 autologous CD4+
T-cells were added to each well. Plates were incubated at 37 C and
5% CO2 for up to 5 days, pulsed with 0.04 MBq of tritium labelled
thymidine (3-H-TdR) (Perkin–Elmer) in 25 ll media and plates
were incubated for another 16 h before being stored at 20 C.
Subsequently, cells were harvested (Tomtec 96, Mach II) onto
glass-fibre mats (Perkin–Elmer) and analysed by liquid-scitillation
counting using a a1450MicroBeta counter (Perkin–Elmer).2.10. MSD cytokine measurement
To evaluate the presence of IFNc, IL-4 and IL-10 in culture
supernatants, the Meso-Scale Discovery (MSD) technology (Gai-
thersburg, MD, USA) was used as previously described (Coad
et al., 2010). Custom coated 7-plex 96-well plates were supplied
by MSD. In brief, MSD plates were blocked with MSD’s proprietary
assay buffer prior to addition of sample or standards. Standards
were serially diluted in MSD dilution buffer with top concentration
of standard shown in parenthesis: IFNc (Endogen, 100 ng ml1); IL-
4 (bovine IL-4 calibrator (MSD), 2 ng ml1) and IL-10 (IAH,
30 Uml1). 25 ll of cell culture supernatant or standards were
added to duplicate wells. Incubations were performed at room
temperature. Following a 2 h incubation, plates were washed and
then incubated for a further 2 h with a combined cocktail of sec-
ondary antibodies conjugated to SulfoTag TM(MSD) (IFNc, IL-4
and IL-10 all from MSD) in MSD dilution buffer. After a final wash,
plates were coated with MSD Buffer-T and luminescence signal
measured on an MSD-6000 reader. Results are shown as calibrated
units extrapolated from standard curves.
2.11. Statistical analysis
Statistical analysis was performed using GraphPad Prism (Ver-
sion 5) by means of 2-way analysis of variance (ANOVA) and post
hoc analyses for multiple significance test comparisons were pro-
vided by Bonferroni correction. Graphical data are presented as
the mean ± SEM. Significance values were set at p < 0.05 for 95%
confidence intervals.3. Results
3.1. Display of the mature E2 protein on the surface of EBY100
S. cerevisiae
EBY100 cells transformed with the pYD1-E2 vector and
untransformed EBY100 cells were grown overnight, stained and
visualised using fluorescent microscopy. Fig. 1 shows expression
of the X-press epitope on the surface of EBY100 cells transformed
with pYD1-E2 (Fig. 1, right panels) can be detected in as little as
12 h after induction with galactose. This expression of the X-press
epitope increased for up to 48 h and then decreased over a period
of time not being detectable at 96 h (data not shown). No X-press
epitope was detected on the surface of wild-type EBY100 cells
(Fig. 1, left panels) for any time point analysed. All further experi-
ments inducing protein expression on the surface of EBY100 cells
were completed using 48 h as the time point at which surface
expression was tested for.
As seen in Fig. 2, EBY100 cells transformed with the pYD1-E2
vector (EBY100-pYD1-E2) (Fig. 2, left hand panels) and grown in
media containing galactose for 48 h stained positive for both the
X-press epitope (Fig. 2, lower panels) and the E2 protein (Fig. 2,
upper panels) as tested using the WB162 antibody. EBY100 cells
transformed with the pYD1 vector (EBY100-pYD1) (Fig. 2, middle
panels) tested positive for the X-press epitope but negative for
the E2 protein. Wild-type EBY100 cells tested negative for both
the X-press epitope and the E2 protein. The data suggest that
working E2 protein is displayed on the surface of EBY100 cells
transformed with the pYD1-E2 vector.
3.2. CXCL8 and ROS production by bovine MØ is dependent on the form
of S. cerevisiae expressing BVDV E2 protein
CXCL8 is produced predominantly by MØ and acts as a potent
chemo-attractant for neutrophils and other granulocytes inducing
Fig. 1. Fluorescent microscope pictures showing staining of X-press epitope on the surface of Wild-type EBY100 and EBY100 transformed with pYD1-E2. Wild-type EBY100 S.
cerevisiae and EBY100 S. cerevisiae transformed with pYD1-E2 were grown as described, and stained using an anti-X-press antibody followed by a secondary anti-mouse-
Alexafluor488 antibody. Cells were viewed by fluorescent microscopy using a 20 objective.
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of infection neutrophils, MØ and other phagocytes engulf antigen
and destroy it by pathways including the ROS pathway. We there-
fore assessed whether recombinant S. cerevisiae induces CXCL-8
and ROS production in bovine MØ. Bovine MØ stimulated with
both, life or heat-inactivated EBY100-pYD1 and EBY100-pYD1-E2
produced significant amounts of CXCL-8 compared with those
stimulated E2 protein alone (Fig. 3A). In contrast, neither
EBY100-pYD1 nor EBY100-pYD1-E2 induced large amounts of
ROS production by MØ. In contrast, DEBY100-pYD1 and
DEBY100-pYD1-E2 induced significantly amounts of ROS.
3.3. Bovine MØ primed with EBY100-pYD-E2 induce stronger CD4+ T-
cell proliferation compared to EBY100-pYD1
Antigen presenting cells such as MØ phagocytose and degrade
antigen which is processed and presented at the cell surface in
the context of MHC class II. Antigen specific CD4+ T cells recognise
this presented antigen through their T-cell receptor and proliferateand release inflammatory cytokines. MØ primed with both
EBY100-pYD1 and EBY100-pYD1-E2 induce significantly higher
CD4+ T-cell proliferation than those primed with the E2 protein
alone (Fig. 4A). Additionally, MØ primed with EBY100-pYD1-E2 in-
duced significantly more CD4+ T-cell proliferation than those
primed with EBY100-pYD1 indicating that a population of CD4+
cells specific for E2 antigenic peptides presented in the context
of MHC class II had been expanded. Controls tested were media
alone, CD4+ cells alone, MØ alone, CD4+ cells co-cultured with
unstimulated MØ and MØ primed with either EBY100-pYD1,
EBY100-pYD1-E2 or E2 alone. None of these controls displayed b-
counts above 1500 cpm for any day tested (data not shown).
3.4. Bovine MØ primed with DEBY100-pYD1-E2 or EBY100-pYD1
induces stronger CD4+ T cell proliferation than those primed with live
yeast
Although live S. cerevisiae expressing hepatitis C virus proteins
has been used in phase II clinical trials in humans (Habersetzer
Fig. 2. Fluorescent microscope pictures showing staining of E2 protein of BVDV and X-press epitope on the surface of transformed EBY100. Wild-type EBY100 S. cerevisiae and
EBY100 S. cerevisiae transformed with pYD1 or pYD1-E2 were grown overnight in YNB-CAA media containing 2% glucose. The following day, cells were pelleted and
resuspended to an OD600 of 0.5–1.0 in YNB-CAA containing 2% galactose. Cultures were grown for 48 h and the E2 protein and X-press epitope were stained on the surface of
the cells using WB162 and X-press antibody respectively followed by the use of a secondary anti-mouse-Alexafluor488 antibody. Cell were viewed by fluorescent microscopy
using a 20 objective.
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option for use in vaccines if it were to be as immunogenic as its live
counter-part. For this reason we tested the capacity of MØ primed
with DEBY100-pYD1-E2 to stimulate proliferation of CD4+ T-cells.
Priming MØ with the DEBY100-pYD1-E2 increases their capacity
to stimulate proliferation of CD4+ T-cells compared to live
EBY100-pYD1-E2 at 5 days of incubation (Fig. 4B). No significant
difference between the proliferative capacities of MØ primed with
live orDEBY100-pYD1-E2 was observed for days 2–4 of incubation.
Controls tested were media alone, MØ alone and CD4+ alone. None
of these controls displayed b-counts above 1500 cpm for any day
tested (data not shown).
3.5. Live EBY100-pYD1-E2 stimulates increased production of INFc and
IL-4
Next, we wanted to determine the cytokine production by CD4+
T cells in response to MØ primed with live and DEBY100-pYD1-E2.
Cell-free supernatants were collected from the same plates as
shown in Fig. 4B, and assayed for INFc, IL-4 and IL-10. Both,
EBY100-pYD1-E2 andDEBY100-pYD1-E2 induced a higher produc-
tion of all three cytokines tested compared to E2 protein alone.
Surprisingly, live EBY100-pYD1-E2 induced more INFc and IL-4
compared to DEBY100-pYD1-E2. This was statistically significant
at days 2, 4 and 5 for INFc and at days 2 and 4 for IL-4 (Fig. 5A
and C). Very little difference is observed between the amount of
IL-10 released in response to live or DEBY100-pYD1-E2 (Fig. 5B).
Controls tested were media alone, MØ alone and CD4+ alone. The
controls did not exceed 1 pg ml1 for INFc, 160 pg ml1 for IL-10
and 0 pg ml1 for IL-4 for any of the days tested (data not shown).
4. Discussion
Several previous studies have highlighted the importance of
dectin-1 as key innate microbial receptor. Dectin-1 collaborateswith TLR2, as well as acting independently, to initiate a wide range
of microbial responses, especially against fungal pathogens. Yeast
such as S. cerevisiae are well documented as being potent activators
of the immune system and therefore do not require the addition of
an additional adjuvant (Romani et al., 2002). In the current study,
we successfully expressed the E2 protein of BVDV on the surface of
the S. cerevisiae EBY100 strain, and started to assess the potential of
this recombinant yeast as a vaccine antigen for BVDV by measuring
the bovine immune response in vitro. We used bovine MØ stimu-
lated with the S. cerevisiae displaying the E2 protein at the surface
and also S. cerevisiae with no expression of the E2 surface protein
and measured their capacity to produce ROS, CXCL8 and also their
capacity to induce proliferation of CD4+ T-cells.
Both yeast types induced significantly more CXCL8 than cells
stimulated with equal amounts of isolated E2 fusion protein. These
data indicate that in our system, the CXCL8 produced by MØ is due
to stimulation of the cells with yeast components. This may be
mainly as a result of TLR stimulation and subsequent NF-kB activa-
tion. However, the induction of CXCL8 may not be completely
dependent on dectin-1, as shown recently in human neutrophils
using depleted zymosan (van Bruggen et al., 2009). When neutro-
phils were stimulated with normal zymosan which contains both
TLR2 and dectin-1 ligands, CXCL8 production were observed (van
Bruggen et al., 2009). The small reduction in CXCL8 production ob-
served in response to heat-killed yeast could be accounted for by a
reduction in the quantity of mannan at the cell surface and there-
fore possibly less TLR activation (Gantner et al., 2005).
Interestingly, our data demonstrates that MØ produce very little
ROS in response to stimulus with live version of EBY100-pYD1 and
EBY100-pYD1-E2. However, when cells are stimulated with heat-
killed versions of the same recombinant yeast, a significant rise
in ROS production is observed. This increase in ROS production
would indicate an increase in dectin-1 ligation as it is well docu-
mented that dectin-1 activation is responsible for ROS production
in phagocytic cells (Gantner et al., 2003; Goodridge and Underhill,
Fig. 3. Live EBY100-pYD1 and EBY100-pYD1-E2 induce CXCL8 whereas heat-
inactivation induces ROS production in bovine MØ. (A) Bovine MØ were stimulated
with media, 2 lg ml1 PMA, 5ppc EBY100-pYD1, 5ppc EBY100-pYD1-E2, 5ppc
DEBY100-pYD1 5ppc DEBY100-pYD1-E2 or 2 mg ml1 E2 for 24 h and cell-free
supernatant was harvested and assayed for CXCL8 content by ELISA. Asterisks
denote a significant (⁄p < 0.05, ⁄⁄p < 0.01) difference from 2 mg ml1 E2 stimulated
group. (B) Bovine MØ were stimulated with media, 5ppc EBY100-pYD1, 5ppc
EBY100-pYD1-E2, 5ppc DEBY100-pYD1 or 5ppc DEBY100-pYD1-E2 and probed for
ROS every 15 min for 2 h. Graphs are representative of 3 biological repeats.
Fig. 4. Bovine MØ primed with EBY100-pYD1-E2 induces a stronger CD4+ T-cell
proliferation compared to MØ primed with EBY100-pYD1, which is further
increased by heat-inactivation. (A) Bovine MØ were seeded in 96-well plates and
primed with 5ppc EBY100-pYD1, 5ppc EBY100-pYD1-E2 or 390 lg ml1 E2 before
addition of CD4+ T-cells. Plates were incubated for 2–5 days before being pulsed
with [3H]-thymidine. Cells were harvested and counts per minute were measured
by liquid-scintillation counting. (B) To assess the effect of heat-inactivation, bovine
MØ were incubated with either 5ppc EBY100-pYD1-E2 or 5ppc DEBY100-pYD1-E2
or 390 lg ml1 E2 and T cell proliferation analysed as described. Asterisks denote a
significant difference between groups (⁄p < 0.05, ⁄⁄⁄p < 0.001). Graphs are repre-
sentative of 3 biological repeats.
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heterophils with the dectin-1 specific antagonist laminarin reduces
their ability to produce ROS in response to stimulus with curdlan (a
b-1,3-glucan) (Nerren and Kogut, 2009). Additionally, experiments
from our lab have demonstrated a significant drop in ROS produc-
tion by MØ in response to zymosan when pre-treated with lami-
narin (data not shown). The fact that heat-killed recombinant
yeast is capable to stimulate ROS production can be explained by
the fact that heat-inactivation exposes more of the dectin-1 ligand
b-glucan at the yeast surface, as shown recently (Gantner et al.,
2005). Furthermore, recent work byWellington et al. has suggested
that live Candida albicans not only inhibits ROS production by
masking b-glucan at its surface but also actively suppresses ROSproduction. However, when using S. cerevisiae, no active suppres-
sion was observed. The authors concluded that this is due to the
fact that S. cerevisiae is non-pathogenic (Wellington et al., 2009).
In our system, this increased recognition of recombinant yeast by
dectin-1 may lead to increased uptake and processing of both
EBY100 and E2 antigen which would be advantageous from the
perspective of using the recombinant yeast as a vaccine. The ma-
ture E2 protein expressed on the yeast surface did not appear to
be affected by the heat-inactivation process as determined by fluo-
rescent staining (data not shown).
The target of any vaccine is to give the recipient an immunolog-
ical memory to the antigen being administered by activating the
adaptive arm of the immune system. In the present study, we
tested the ability of MØ primed with recombinant yeast expressing
E2 protein to stimulate proliferation of purified autologous CD4+ T-
cells derived from BVDV antibodies and virus-free animals, and
have compared it to those primed with EBY100 yeast without sur-
face E2 protein (Fig. 4A). MØ primed with either EBY100-pYD1 or
Fig. 5. Bovine MØ primed with live EBY100-pYD1-E2 induce a stronger INFc and
IL-4, but similar IL-10 production compared with those primed with DEBY100-
pYD1-E2. Bovine MØ were seeded in 96-well plates and primed with 5ppc EBY100-
pYD1-E2, 5ppc DEBY100-pYD1-E2 or 390 lg ml1 E2. CD4+ T-cells were added and
plates were incubated for 2–5 days before cell-free supernatants were harvested
and assayed for INFc, IL-4 and IL-10 content as described. Asterisks denote a
significant difference between groups. (⁄p < 0.05, ⁄⁄⁄p < 0.001). Graphs are repre-
sentative of 3 biological repeats.E2, 5ppc DEBY100-pYD1 or 5ppc DEBY100-pYD1-
E2 and probed for ROS every 15 min for 2 h. Graphs are representative of 2
biological repeats.
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with those primed with the E2 protein alone. We are fully aware of
the fact that the stimulation of naïve CD4+ T cells should not occur
when using MØ as antigen presenting cells. We can only assume at
the moment that either the MØ prepared using the method de-
scribed possess functions associated normally with dendritic cells,or that the use of yeast particles induces such a strong stimulatory
signal for MØ that these are able to subsequently drive T cell pro-
liferation. Our data indicate that either yeast antigen readily enters
endocytic processing pathways and is expressed on the cell surface
in the context of MHC II, or stimulates such a strong innate im-
mune response with the secretion of pro-inflammatory cytokines
that it drives T cell proliferation. Additionally, priming MØ with
EBY100-pYD1-E2 induced a significantly stronger CD4+ prolifera-
tive response at day 4 and 5 than priming with EBY100-pYD1.
Thus, in addition to the proliferation of potential yeast antigen spe-
cific CD4+ cell, an E2 specific CD4+ T cell population may expand.
Our data are in line with recent data using murine dendritic cells
primed with S. cerevisiae expressing recombinant ovalbumine
(Stubbs et al., 2001). Here, dendritic cells primed with as little as
5 recombinant yeast particles induced CD4+ proliferation to the
same degree as those primed with saturating amounts of ovalbu-
min peptide. The authors also found that stimulation of dendritic
cells with yeast induced up-regulation of CD80, CD86, CD40,
CD54 and MHC II as well as an increase in IL-12 production. These
increases were comparable to stimulation with LPS. These data
clearly demonstrate the adjuvant-like properties of S. cerevisiae
yeast and offer some explanation of why conjugating protein anti-
gen to whole yeast appears to increase the cellular immune re-
sponse to this antigen. Given the differences seen between live
and heat-inactivated yeast, and given the fact that a heat-inacti-
vated delivery system still showing immunogenicity, we also as-
sessed the ability of heat-killed EBY100-pYD1-E2 primed MØ to
stimulate CD4+ proliferation, and compared the INFc, IL-4 and IL-
10 production induced in the responding T cells.
In correlation with the ROS data showing increased ROS pro-
duction in response to heat-killed EBY100-pYD1-E2, a stronger
CD4+ T-cell proliferative response was seen in MØ primed with
heat-killed EBY100-pYD1-E2 after 5-days of incubation (Fig. 4B).
Similar as for the ROS data, this may be a result of more b-glucan
being exposed at the yeast surface (Gantner et al., 2005), resulting
in increased dectin-1 ligation and therefore facilitate uptake of
EBY100-pYD1-E2 by MØ. Indeed, work by Lu et al. and by Franzus-
off et al. has demonstrated that immunisation with inactivated S.
cerevisiae expressing tumour antigens elicits an equal anti-tumour
response to immunisation with their live counter-parts (Ardiani
et al., 2010; Franzusoff et al., 2005; Lu et al., 2004), but to our
knowledge this is the first report that recombinant heat-inacti-
vated S. cerevisiae may actually increase the adaptive immune.
We were expecting to see an increased amount of INFc produced
by T-cell assays co-cultured with MØ exposed to DEBY100-pYD1-
E2 compared to those exposed to live yeast, reflecting the in-
creased CD4+ proliferation (Fig. 4B). Surprisingly this was not the
case. In fact, higher INFc and IL-4 concentrations were measured
in supernatants of co-cultures where live EBY100-pYD1-E2 was
used (Fig. 5A and C), whereas amounts of IL-10 were similar
(Fig. 5B). Whereas we can currently not fully explain this observa-
tion, it is possible that heat-inactivated, but not live yeast induces
an anti-inflammatory state in MØ, without affecting the ability of
these cells to stimulate T cells. Such effect has been recently
described for Murine macrophages (RAW 264.7) using either
heat-inactivated or live C. albicans on the proteomics level
(Martinez-Solano et al., 2009).
In conclusion, both live and heat-killed S. cerevisiae are an
attractive vaccine vehicle for delivering the weakly immunogenic
proteins to APC in order to stimulate cellular immunity directed
against this protein. Such delivery system could not only improve
current BVDV vaccine strategies, but potentially any vaccine which
relies on such protein antigen. The ease with which S. cerevisiae can
be genetically manipulated means that potentially any antigenic
protein could be expressed at the yeast surface, potentially
expressing even more than one immunogenic protein, either from
114 R. Patterson et al. / Developmental and Comparative Immunology 37 (2012) 107–114the same pathogen or derived from different pathogens. Further-
more, such delivery-systems could subsequently allow for the dis-
crimination of vaccinated versus naturally infected animals.
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